The objective of this study is to evaluate the efficacy of neoadjuvant stereotactic body radiation therapy (SBRT) in combination with chemotherapy and immunotherapy, prior to radical surgery, in enhancing the 2-year event-free survival rate and overall survival rate in patients diagnosed with locally advanced oral or HPV-unrelated oropharyngeal cancer.
Histologically and/or cytologically confirmed treatment-naïve oral squamous cell carcinoma or HPV-negative oropharyngeal squamous cell carcinoma.
Clinical stage III -Ⅳa (8th edition of AJCC).
Age: 18 to 75 years old.
According to the Eastern Cooperative Oncology Group (ECOG) criteria (with a performance status score of 0 or 1).
Patients with concurrent other malignant tumors
Patients with known or suspected autoimmune diseases, including dementia and epilepsy.
Patients with severe mental disorders at the same time
Patients with necrotic lesions who are assessed by the investigator as having a risk of massive hemorrhage